Sunshine Biopharma (SBFM) Equity Average (2011 - 2026)

Sunshine Biopharma has reported Equity Average for 14 years, with the latest figure at $22.3 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 3.57% year-over-year to $22.3 million; the trailing twelve-month figure through Mar 2026 stood at $22.3 million (down 3.57% YoY), and the FY2025 full-year result was $23.3 million, up 4.1% from the prior year.
• Equity Average for Q1 2026 stood at $22.3 million, down from $23.6 million in the prior quarter.
• The five-year high for Equity Average was $41.1 million in Q3 2022, with the low at $6.8 million in Q1 2022.
• Historically, Equity Average has averaged $23.9 million across 5 years, with a median of $23.6 million in 2025.
• Annual changes were most pronounced in 2022 — Equity Average soared 6544.31% — and 2023, when it tumbled 45.21%.
• Sunshine Biopharma's Equity Average stood at $31.0 million in 2022, then plunged by 30.38% to $21.6 million in 2023, then grew by 12.44% to $24.3 million in 2024, then declined by 2.68% to $23.6 million in 2025, then slipped by 5.68% to $22.3 million in 2026.
• The last three Equity Average figures came in at $22.3 million (Q1 2026), $23.6 million (Q4 2025), and $24.9 million (Q3 2025), per Business Quant data.